Twist Bioscience announced the early‑access launch of its Complex Genes platform on May 4 2026. The new offering expands the company’s silicon‑based DNA synthesis technology to reliably produce sequences up to 7,000 base pairs within 15 business days, a capability that was previously limited by sequence length and complexity.
The platform delivers a 99.5% acceptance rate for clonal gene orders and a 99.9% acceptance rate for all DNA products, a significant improvement over the company’s prior synthesis rates. It can handle a wide range of challenging sequence types—including short tandem repeats, inverted repeats, long repeats, homopolymers up to 30 base pairs, and regions of high or low GC content—making it well suited for the intricate libraries required by AI‑guided protein design and nucleic acid therapeutics.
Early‑access customers are already placing orders, and the platform is expected to drive additional revenue in the DNA Synthesis and Protein Solutions segment, which grew 27% year‑over‑year in Q1 2026. The launch aligns with Twist’s strategy to capture a larger share of the expanding AI‑driven drug discovery market and reinforces its competitive moat by offering a technology that is difficult for rivals to replicate.
CEO Emily M. Leproust emphasized the platform’s strategic importance: “As research in nucleic acid therapeutics and AI‑guided protein design accelerates, scientists need a reliable partner to consistently deliver genes rapidly at scale and with more complex sequences.” The announcement signals a major operational milestone that could accelerate discovery timelines for customers and strengthen Twist’s position in a high‑growth segment.
The Complex Genes platform is a key component of Twist’s broader portfolio, which has already delivered strong revenue growth in Q1 2026, with total revenues of $103.7 million—up 17% from Q1 2025—and a 27% year‑over‑year increase in the DNA Synthesis and Protein Solutions segment. The platform’s launch is expected to contribute to continued revenue expansion and further solidify Twist’s leadership in synthetic biology.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.